Akero Therapeutics Inc buy UBS Group AG
Start price
31.01.25
/
50%
€52.08
Target price
31.01.26
€105.08
Performance (%)
-9.81%
Price
08.12.25
€46.97
Summary
This prediction is currently active. With a performance of -9.81%, the BUY prediction by UBS_Group_AG is trending in the wrong direction. This prediction currently runs until 31.01.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akero Therapeutics Inc | 0.278% | 0.278% |
| iShares Core DAX® | 0.734% | 1.458% |
| iShares Nasdaq 100 | -2.686% | -0.146% |
| iShares Nikkei 225® | -2.261% | -2.729% |
| iShares S&P 500 | -1.346% | 0.467% |
Comments by UBS_Group_AG for this prediction
In the thread Akero Therapeutics Inc diskutieren
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $42.00 to $109.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Stopped prediction by UBS_Group_AG for Akero Therapeutics Inc
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€26.60
05.03.24
05.03.24
€38.62
05.03.25
05.03.25
54.62%
06.03.25
06.03.25
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€14.00
12.10.23
12.10.23
€37.01
12.10.24
12.10.24
92.86%
13.10.24
13.10.24
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€46.20
28.08.23
28.08.23
€76.75
28.08.24
28.08.24
-48.68%
29.08.24
29.08.24